Latest News and Press Releases

JANUARI – SEPTEMBER 2020 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Rörelsens kostnader uppgick till MSEK -19,8 (-22,9)Resultatet före och efter skatt uppgick till MSEK -19,8 (-22,9)Resultat per...

A scientific review article “Toll-Like Receptor 9 Agonists in Cancer”, written by Dr Davar Diwakar et al, a prominent immune-oncology research group in Pittsburgh (US), was recently published in the...

UPPSALA, SWEDEN – LIDDS AB (publ) announces that intratumoral injection of NZ-TLR9, NanoZolid (NZ) formulation of a Toll-Like Receptor 9 (TLR9), results in strong antitumoral efficacy combined with...

UPPSALA, SWEDEN – LIDDS AB (publ) ("LIDDS" or the "Company") announced today the outcome of the subscription of shares in the incentive programs 2017/2020. Last day of subscription was on October 15,...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 %...

APRIL – JUNI 2020 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Rörelsens kostnader uppgick till MSEK –5,3 (-8,4)Resultatet före och efter skatt uppgick till MSEK -5,3 (-8,4)Resultat per aktie...

UPPSALA, SWEDEN – LIDDS AB (publ) announces that its licensee Jiangxi Puheng Pharma is currently preparing documentation for an application targeting a newly issued regulatory guideline in China on...

LIDDS AB ("LIDDS" eller "Bolaget") offentliggjorde den 11 juni 2020 att styrelsen, med stöd av årsstämmans bemyndigande, beslutat att genomföra en nyemission med företrädesrätt för befintliga...

  LIDDS AB (“LIDDS” or the “Company”) announced on 11 June 2020 that the Board of Directors, pursuant to the authorization granted by the annual general meeting, has resolved to carry out a new...

LIDDS AB (“LIDDS” or the “Company”) announced on 11 June 2020 that the Board of Directors, pursuant to the authorization granted by the annual general meeting, has resolved to carry out, inter alia, a...